These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Sublingual immunotherapy and subcutaneous immunotherapy: issues in the United States. Greenberger PA; Ballow M; Casale TB; Platts-Mills TA; Sampson HA J Allergy Clin Immunol; 2007 Dec; 120(6):1466-8. PubMed ID: 17936891 [No Abstract] [Full Text] [Related]
43. Assessing the safety of subcutaneous immunotherapy dose adjustments. Webber CM; Calabria CW Ann Allergy Asthma Immunol; 2010 Nov; 105(5):369-75. PubMed ID: 21055663 [TBL] [Abstract][Full Text] [Related]
44. [Controlled immunotherapy of bronchial asthma]. Droszcz W; Pawłowicz A Pol Tyg Lek; 1983 Jul; 38(27):829-30. PubMed ID: 6657520 [No Abstract] [Full Text] [Related]
45. [Diagnosis and specific desensitizing treatment of allergic asthma]. Bonifazi F; Sanguinetti CM; Vennarucci LS Minerva Med; 1980 Jan; 71(3):171-6. PubMed ID: 7354934 [No Abstract] [Full Text] [Related]
46. [Specific immunotherapy in desensitization of allergic patients. Oral administration instead of injections? (interview by Andrea Warpakowski)]. Grevers G MMW Fortschr Med; 2003 May; 145(18):18. PubMed ID: 12808815 [No Abstract] [Full Text] [Related]
47. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Senti G; von Moos S; Kündig TM Allergy; 2011 Jun; 66(6):798-809. PubMed ID: 21518374 [TBL] [Abstract][Full Text] [Related]
48. [Clinical study on hyposensitization therapy of bronchial asthma]. Ito K Arerugi; 1968 Mar; 17(3):164-78. PubMed ID: 5677704 [No Abstract] [Full Text] [Related]
49. [Recombinant allergens; allergy vaccine in the future?. Interview by Dr. Barbara Scholtissek]. Valenta R Wien Med Wochenschr; 1999; 149(14-15):450-1. PubMed ID: 10584293 [No Abstract] [Full Text] [Related]
50. [Allergic rhinitis. This year the pollen count is expected to be high]. Hellmann A MMW Fortschr Med; 2006 May; 148(21):51-2. PubMed ID: 16796189 [No Abstract] [Full Text] [Related]
51. A controlled trial of immunotherapy for asthma in allergic children. Adkinson NF; Eggleston PA; Eney D; Goldstein EO; Schuberth KC; Bacon JR; Hamilton RG; Weiss ME; Arshad H; Meinert CL; Tonascia J; Wheeler B N Engl J Med; 1997 Jan; 336(5):324-31. PubMed ID: 9011784 [TBL] [Abstract][Full Text] [Related]
52. Shooting for a faster approach to the immunotherapy target: will cluster become conventional? Cox LS Ann Allergy Asthma Immunol; 2009 Mar; 102(3):177-8. PubMed ID: 19354062 [No Abstract] [Full Text] [Related]
53. Local immunotherapy in chronic allergic rhinitis and bronchial asthma with allergen aerosols. III. Dynamics of some sensitization and immunity indexes. Moshkevich VS; Tsarevskaya LA; Nurpeisov TN; Nugmanova JS; Tsoy VP Allergol Immunopathol (Madr); 1986; 14(4):277-85. PubMed ID: 3776777 [TBL] [Abstract][Full Text] [Related]
54. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799 [TBL] [Abstract][Full Text] [Related]
55. An evidence based overview of sublingual immunotherapy in children. Scala G; Di Rienzo Businco A; Ciccarelli A; Tripodi S Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):23-6. PubMed ID: 19944006 [TBL] [Abstract][Full Text] [Related]
60. Current aspects in the immunopharmacology of asthma. Assem ES Med Biol; 1976 Dec; 54(6):369-82. PubMed ID: 12422 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]